WLBU2 acetate

WLBU2 acetate is a engineered cationic antimicrobial peptide ( eCAP ) that overcomes the environmental sensitivity of natural antimicrobial peptides (AMPs). WLBU2 acetate exhibits rapid bactericidal effect, with the MIC values of ≤ 10 μM against both Gram-negative and Gram-positive bacteria including MRSA, vancomycin-resistant enterococci, K. pneumoniae, E.aerogenes, E. cloacae, Escherichia coli, et, al. WLBU2 acetate prevents P. aeruginosa biofilm growth and retains its activity in an environment rich in mucus, low pH and high salt concentrations without negative effects on human airway epithelial cells. WLBU2 acetate can be used for the studies of cystic fibrosis (CF) and Pseudomonas aeruginosa infections ^{[1] [2]}.

In Vitro, WLBU2 (5-90 μM, 24 h (abiotic surface); 10-100 μM, 5 h (CFAECs)) acetate prevents abiotic P. aeruginosa biofilms on an abiotic surface and on human cystic fibrosis airway epithelial cells (CFAECs)^[1]. WLBU2 (50 μM, 5 h) acetate retains biofilm prevention activity in high salt (100 mM Nacl) and low pH (6.5-7.0) environments in CFAECs^[1]. WLBU2 (20 μM, 5 h) acetate shows synergistic effect when combined with Tobramycin, ciprofloxacin, Ceftazidime, and Meropenem, but has no synergistic effect with Colistin in CFAECs^[1]. WLBU2 acetate exhibits a MIC value of 7.943 μM against Klebsiella pneumoniae and a MIC value of 7.484 μM against clinical isolates of Acinetobacter baumannii, with the MBC values of the bacterial isolates being identical to their respective MIC values, indicating its bactericidal effect^[2].

References:
[1]. Lashua LP, et al. Engineered cationic antimicrobial peptide (eCAP) prevents Pseudomonas aeruginosa biofilm growth on airway epithelial cells. J Antimicrob Chemother. 2016 Aug;71(8):2200-7.
[2]. Elsalem L, Khasawneh A, Al Sheboul S. WLBU2 Antimicrobial Peptide as a Potential Therapeutic for Treatment of Resistant Bacterial. Turk J Pharm Sci. 2022 Feb 28;19(1):110-116.